MarkSchoenbergMD

PubMed

• 2 citations
  Natural History of Multiple Recurrences in Intermediate-Risk Non-Muscle Invasive Bladder Cancer: Lessons From a Prospective Cohort.
  Vidit Sharma, Karim Chamie, Mark Schoenberg, Valerie S Lee, Katherine Fero, Patrick Lec, Julie R Munneke, David S Aaronson, Lawrence H Kushi, Charles P Quesenberry, Li...> ;Urology. 2023 Mar 1
• 2 citations
  Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center study.
  Kamal S Pohar, Sanjay Patel, Yair Lotan, Edouard Trabulsi, Michael Woods, Tracy Downs, William C Huang, Jeffrey Jones, Jennifer Taylor, Michael O'Donnell, Trinity J Bi...> ;Urologic Oncology. 2022 Aug 1
• 4 citations
  Safety and Efficacy of Reproductive organ-sparing radical cystectomy in women with variant histology and advanced stage
  Sunil H. Patel, Shirley Wang, Meredith R. Metcalf, Natasha Gupta, Andrew T. Gabrielson, Esther Lee, Mary Rostom, Phil Pierorazio, Armine K. Smith, Noah Hahn, Mark Scho...> ;Clinical Genitourinary Cancer. 2021 Nov 15
• 10 citations
  Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2...
  K. Kent Chevli, Neal D. Shore, Andrew Trainer, Angela B. Smith, Daniel Saltzstein, Yaron Ehrlich, Jay D. Raman, Boris Friedman, Richard D’Anna, David L. Morris, Brian ...> ;The Journal of Urology. 2021 Aug 26
• Rethinking the Treatment of Recurrent Nonmuscle-Invasive Bladder Cancer
  Mark P. Schoenberg, Gary D. Steinberg> ;The Journal of Urology. 2021 Mar 8
• 6 citations
  Pharmacokinetics of UGN-101, a mitomycin-containing reverse thermal gel instilled via retrograde catheter for the treatment of low-grade upper tract urothelial carcinoma.
  Ahmad Shabsigh, Nir Kleinmann, Angela B. Smith, Douglas S. Scherr, Elyse Seltzer, Mark P. Schoenberg, Seth P. Lerner> ;Cancer Chemotherapy and Pharmacology. 2021 Mar 7
• 38 citations
  Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
  Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, Adam C. Reese, Michael J. Biles, Kelly T. Harris, George J. Netto, Andres Matoso, Jean H. Hoffman-Censits, Noah M. Ha...> ;European Urology. 2021 Mar 1
• 4 citations
  Finasteride Use and Risk of Bladder Cancer in a Multiethnic Population.
  Denzel Zhu, Abhishek Srivastava, Ilir Agalliu, Ethan Fram, Evan Kovac, Ahmed Aboumohamed, Mark P. Schoenberg, Alexander Sankin> ;The Journal of Urology. 2021 Feb 22
• 9 citations
  Complications Associated With Ureteroscopic Management of Upper Tract Urothelial Carcinoma.
  Jennifer M Linehan, Mark P. Schoenberg, Elyse Seltzer, Kim Thacker, Angela B. Smith> ;Urology. 2021 Jan 1
• 72 citations
  Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, pha...
  Nir Kleinmann, Surena F. Matin, Phillip M. Pierorazio, John L. Gore, Ahmad Shabsigh, Brian Hu, Karim Chamie, Guilherme Godoy, Scott G. Hubosky, Marcelino E. Rivera, Mi...> ;The Lancet. Oncology. 2020 Jun 1
• 9 citations
  An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine/docetaxel for nonmuscle-invasive bladder cancer.
  Marcus J. Daniels, Emily Barry, Niv Milbar, Mark P. Schoenberg, Trinity J. Bivalacqua, Alexander Sankin, Max Kates> ;Urologic Oncology. 2020 Feb 1
• 10 citations
  Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancer.
  Marcus J. Daniels, Emily Barry, Mark P. Schoenberg, Donald L. Lamm, Trinity J. Bivalacqua, Alexander Sankin, Max Kates> ;Urologic Oncology. 2020 Jan 1
• 2 citations
  Human urothelial bladder cancer generates a clonal immune response: The results of T-cell receptor sequencing.
  Alexander Sankin, Damini Chand, Mark P. Schoenberg, Xingxing Zang> ;Urologic Oncology. 2019 Nov 1
• 19 citations
  Implications of micropapillary urothelial carcinoma variant on prognosis following radical cystectomy: A multi-institutional investigation
  Anirban P. Mitra, Adrian Fairey, Eila C. Skinner, Stephen A. Boorjian, Igor Frank, Mark P. Schoenberg, Trinity J. Bivalacqua, M. Eric Hyndman, Adam C. Reese, Gary D. S...> ;Urologic Oncology. 2019 Jan 1
• 30 citations
  SIU–ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer
  Jeffrey J. Leow, Jens Bedke, Karim Chamie, Justin W. Collins, Siamak Daneshmand, Petros Grivas, Axel Heidenreich, Edward M. Messing, Trevor J. Royce, Alexander Sankin,...> ;World Journal of Urology. 2019 Jan 1
• 10 citations
  Patient-reported outcomes of blue-light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: results from a prospective multicentre study.
  Angela B. Smith, Siamak Daneshmand, Sanjay Patel, Kamal S. Pohar, Edouard J. Trabulsi, Michael Woods, Tracy M. Downs, William C. Huang, Jennifer Taylor, Jeffrey A. Jon...> ;BJU International. 2019 Jan 1
• 7 citations
  Immune Checkpoint B7x (B7-H4/B7S1/VTCN1) is Over Expressed in Spontaneous Canine Bladder Cancer: The First Report and its Implications in a Preclinical Model.
  Damini Chand, Alexander Sankin, Xiaoxin Ren, Juan Lin, Mark P. Schoenberg, Deborah W. Knapp, Xingxing Zang, Deepika Dhawan> ;Bladder Cancer. 2019 Jan 31
• 36 citations
  Hospital Charges and Length of Stay Following Radical Cystectomy in the Enhanced Recovery After Surgery Era.
  Alice Semerjian, Niv Milbar, Max Kates, Michael A. Gorin, Hiten D. Patel, Heather J. Chalfin, Steven M. Frank, Christopher L. Wu, William W. Yang, Deb Hobson, Lindsay ...> ;Urology. 2018 Jan 1
• 60 citations
  Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study
  Siamak Daneshmand, Sanjay G. Patel, Yair Lotan, Kamal S. Pohar, Edouard J. Trabulsi, Michael Woods, Tracy M. Downs, William C. Huang, Jeffrey A. Jones, Michael A. O’Do...> ;The Journal of Urology. 2018 May 1
• 47 citations
  Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer
  Niv Milbar, Max Kates, Meera Chappidi, Filippo Pederzoli, Takahiro Yoshida, Alexander Sankin, Phillip M. Pierorazio, Mark P. Schoenberg, Trinity J. Bivalacqua> ;Bladder Cancer. 2017 Oct 27
• 9 citations
  The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1
  Alexander Sankin, Peter John, Benjamin A. Gartrell, Mark P. Schoenberg, Xingxing Zang> ;Urologic Oncology. 2017 May 8
• 166 citations
  The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3
  Murali Janakiram, Urvi A Shah, Weifeng Liu, Aimin Zhao, Mark P. Schoenberg, Xingxing Zang> ;Immunological Reviews. 2017 Mar 1
• 12 citations
  Biomanufacturing Seamless Tubular and Hollow Collagen Scaffolds with Unique Design Features and Biomechanical Properties
  Anirudha Singh, David S. Lee, Nikolai A. Sopko, Hotaka Matsui, Praveena Sabnekar, Xiaopu Liu, Jennifer H. Elisseeff, Mark P. Schoenberg, Kenneth J. Pienta, Trinity J. ...> ;Advanced Healthcare Materials. 2017 Mar 1
• A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
  Zhou TC, Sankin AI, Porcelli SA, Perlin DS, Schoenberg MP, Zang X> ;Urol. Oncol.. 2017-01-01
• Accuracy of urethral frozen section during radical cystectomy for bladder cancer.
  Kates M, Ball MW, Chappidi MR, Baras AS, Gordetsky J, Sopko NA, Brant A, Pierorazio PM, Epstein JI, Schoenberg MP, Bivalacqua TJ> ;Urol. Oncol.. 2016-12-01
• Join now to see all

Journal Articles

• The William/Buscarini/Stein Article Reviewed  
  Schoenberg MP, Onc
• In-hospital death and hospital-acquired complications among patients undergoing partial cystectomy for bladder cancer in the United States  
  Kates M, Gorin MA, Deibert CM, Pierorazio PM, Schoenberg MP, McKiernan JM, Bivalacqua TJ, Urol Oncol, 1/1/2014
• TERT Promoter Mutations Occur Early in Urothelial Neoplasia and Are Biomarkers of Early Disease and Disease Recurrence in Urine  
  Kinde I, Munari E, Faraj SF, Hruban RH, Schoenberg M, Bivalacqua T, Allaf M, Springer S, Wang Y, Diaz LA Jr, Kinzler KW, Vogelstein B, Papadopoulos N, Netto GJ, Cancer Res, 12/1/2013
• Clinical Trial Design for the Development of New Therapies for Nonmuscle-invasive Bladder Cancer: Report of a Food and Drug Administration and American Urological Asso...  
  Jarow JP, Lerner SP, Kluetz PG, Liu K, Sridhara R, Bajorin D, Chang S, Dinney CP, Groshen S, Morton RA, O'Donnell M, Quale DZ, Schoenberg M, Seigne J, Vikram B, Urology, 12/1/2013
• Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after ...  
  Tilki D, Shariat SF, Lotan Y, Rink M, Karakiewicz PI, Schoenberg MP, Lerner SP, Sonpavde G, Sagalowsky AI, Gupta A, BJU Int, 6/1/2013
• Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder  
  Kassouf W, Svatek RS, Shariat SF, Novara G, Lerner SP, Fradet Y, Bastian PJ, Aprikian A, Karakiewicz PI, Fritsche HM, Dinney CP, Tilki D, Kamat AM, Izawa JI, Ficarra V..., Urol Oncol, 5/1/2013
• Predictors of cancer-specific mortality after disease recurrence following radical cystectomy  
  Rink M, Lee DJ, Kent M, Xylinas E, Fritsche HM, Babjuk M, Brisuda A, Hansen J, Green DA, Aziz A, Cha EK, Novara G, Chun FK, Lotan Y, Bastian PJ, Tilki D, Gontero P, Py..., BJU Int., 3/1/2013
• Upper Tract Urothelial Carcinoma Collaboration (UTUCC) Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial ...  
  Rink M, Ehdaie B, Cha EK, Green DA, Karakiewicz PI, Babjuk M, Margulis V, Raman JD, Svatek RS, Fajkovic H, Lee RK, Novara G, Hansen J, Daneshmand S, Lotan Y, Kassouf W..., Eur Urol, 10/1/2012
• Plagiarism  
  Droller MJ; ad hoc Committee on Plagiarism, Bahnson RR, Lerner SP, Schoenberg M, Thalmann GA, Urol OncolUrol Oncol, 9/1/2012
• Ureteral Stents Placed at the Time of Urinary Diversion Decreases Postoperative Morbidity  
  Mullins JK, Guzzo TJ, Ball MW, Pierorazio PM, Eifler J, Jarrett TW, Schoenberg MP, Bivalacqua TJ, Urol Int, 1/4/2012
• Smoking Knowledge Assessment and Cessation Trends in Patients With Bladder Cancer Presenting to a Tertiary Referral Center  
  Guzzo TJ, Hockenberry MS, Mucksavage P, Bivalacqua TJ, Schoenberg MP, Urology, 1/1/2012
• The use of regenerative medicine in the management of invasive bladder cancer  
  Hyndman ME, Kaye D, Field NC, Lawson KA, Smith ND, Steinberg GD, Schoenberg MP, Bivalacqua TJ, Adv Urol, 1/1/2012
• The presence of circulating tumor cells does not predict extravesical disease in bladder cancer patients prior to radical cystectomy  
  Guzzo TJ, McNeil BK, Bivalacqua TJ, Elliott DJ, Sokoll LJ and Schoenberg MP, Urol Oncol, 1/1/2012
• Coronary stent management in elective genitourinary surgery  
  Gupta AD, Streiff M, Resar J, Schoenberg M, BJU Int, 12/22/2011
• Clinical benefits of a multivariate prediction model for bladder cancer: a decision analytic approach Erratum  
  Vickers AJ, Cronin AM, Kattan MW, Gonen M, Scardino PT, Milowsky MI, Dalbagni G, Bochner BH; International Bladder Cancer Consortium, Cancer, 8/1/2011
• Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder  
  Wang H, Albadine R, Magheli A, Guzzo TJ, Ball MW, Hinz S, Schoenberg MP, Netto GJ, Gonzalgo ML, Urol Oncol, 3/9/2011
• Cancer incidence and mortality among workers exposed to benzidine  
  Brown SC, Alberts R, Schoenberg M, Am J Ind Med, 2/15/2011
• Disease-Free Survival at 2 or 3 Years Correlates With 5-Year Overall Survival of Patients Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer  
  Sonpavde G, Khan MM, Lerner SP, Svatek RS, Novara G, Karakiewicz PI, Skinner E, Tilki D, Kassouf W, Fradet Y, Dinney CP, Fritsche HM, Izawa JI, Bastian PJ, Ficarra V, ..., J Urol, 2/1/2011
• Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy  
  Schultz L, Albadine R, Hicks J, Jadallah S, DeMarzo AM, Chen YB, Neilsen ME, Gonzalgo ML, Sidransky D, Schoenberg M, Netto GJ, Cancer, 12/1/2010
• The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder  
  Svatek RS, Shariat SF, Lasky RE, Skinner EC, Novara G, Lerner SP, Fradet Y, Bastian PJ, Kassouf W, Karakiewicz PI, Fritsche HM, Müller SC, Izawa JI, Ficarra V, Sagalow..., Clin Cancer Res, 9/1/2010
• Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients  
  Tilki D, Svatek RS, Novara G, Seitz M, Godoy G, Karakiewicz PI, Kassouf W, Fradet Y, Fritsche HM, Sonpavde G, Izawa JI, Ficarra V, Lerner SP, Schoenberg MP, Stief CG, ..., J Urol, 9/1/2010
• Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen  
  Pierorazio PM, Guzzo TJ, Han M, Bivalacqua TJ, Epstein JI, Schaeffer EM, Schoenberg MP, Walsh PC, Partin AW, Urology, 9/1/2010
• Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients  
  Novara G, Svatek RS, Karakiewicz PI, Skinner E, Ficarra V, Fradet Y, Lotan Y, Isbarn H, Capitanio U, Bastian PJ, Kassouf W, Fritsche HM, Izawa JI, Tilki D, Dinney CP, ..., J Urol, 6/1/2010
• International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy  
  Shariat SF, Svatek RS, Tilki D, Skinner E, Karakiewicz PI, Capitanio U, Bastian PJ, Volkmer BG, Kassouf W, Novara G, Fritsche HM, Izawa JI, Ficarra V, Lerner SP, Sagal..., BJU Int, 5/1/2010
• Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients  
  Tilki D, Reich O, Svatek RS, Karakiewicz PI, Kassouf W, Novara G, Ficarra V, Chade DC, Fritsche HM, Gerwens N, Izawa JI, Lerner SP, Schoenberg MP, Stief CG, Skinner E,..., J Urol, 5/1/2010
• Join now to see all

Books/Book Chapters

• Campbells Urology 
  Chapter: Chapter 78: Management of Invasive and Metastatic Bladder Cancer. 
  Schoenberg MW.B. SaundersEdition 8th,2002
• Atlas of Genitourinary Oncology 
  Chapter: Chapter 4: Bladder and other urothelial malignancies. 
  Linn JF, Halachmi S and Schoenberg MPW.B. Saunders Company2002
• AUA Update Series 
  Chapter: Molecular diagnostics for bladder cancer. 
  Han M and Schoenberg MAmerican Urological Association, Inc., Office of Education, Houston, TX2001
• The Guide to Living with Bladder Cancer. 
  Mark P. Schoenberg, M.D.The Johns Hopkins University Press, Baltimore, MD2000
• Das oberflachliche Harnblasen-karzinom - eine lebenslange panurotheliale Erkrankung? 
  Chapter: Molecular diagnostics and bladder cancer. 
  Page 45 - 51Schoenberg MLogos Verlag, Berlin1996
• Hormones and Cancer 
  Chapter: Androgen receptors in human prostate cancer: heterogeneous expression, gene mutations and polymorphic variants. 
  Page 449 - 496Hakimi JM, Rondinelli RH, Schoenberg MP, Barrack ERBirkhauser, Boston1996
• Join now to see all

Abstracts/Posters

• A Post-Chemotherapy Restaging Evaluation Improves the Correlation of Clinical and Pathological Stage in Patients Treated with Neoadjuvant Chemotherapy and Radical Cyst...
  Adam Reese, Mark Ball, Trinity Bivalacqua, George Netto, Mark Schoenberg, AUA, San Diego, CA, 5/7/2013
• Impact of micropapillary urothelial carcinoma variant histology on survival after radical cystectomy: a multi-institutional analysis.
  Adrian Fairey, Eila Skinner, Stephen Boorjian, Jeffrey Wang, Igor Frank, Mark Schoenberg, Eric Hyndman, Adam Reese, Gary Steinberg, Michael Large, Christina Hulsbergen..., AUA, San Diego, CA, 5/7/2013
• Muscle-invasive bladder cancer in the elderly. Plenary Presentation
  Badrinath Konety, Gary Steinberg and Mark Schoenberg, AUA, San Diego, CA, 5/7/2013
• Impact of Surgical Volume on Perioperative Outcomes and Costs of Radical Cystectomy: Analysis of the Maryland Health Services Cost Review Commission Database.
  Michael Gorin, Max Kates, Jeffrey Mullins, Phillip Pierorazio, Deborah Kaye, Brian Matlaga, Mark Schoenberg, Trinity Bivalacqua, AUA, San Diego, CA, 5/7/2013
• Overexpression of IGF1R Predicts Outcome in Invasive Urothelial Carcinoma of Urinary Bladder.
  Nilda Gonzalez-Roibon, Jenny Kim, Alcides Chaux, Enrico Munari, Sheila Faraj, Carla Ellis, Rajni Sharma, Trinity Bivalacqua, Mark Schoenberg, Michael Carducci, George ..., AUA, San Diego, CA, 5/7/2013
• Moderated Poster. “Bladder Cancer: Metastatic Disease/Staging. 1906: Positive Surgical Margins Contribute to Delayed Failures in Patients Undergoing Radical Cystectomy...
  Edwin Morales, Shahrokh Shariat, Pierre Karakiewicz, Bjorn Volkmer, Wassim Kassouf, Yves Fradet, Giacomo Novara, Hans-Martin Fritsche, Patrick Bastian, Jonathan Izawa,..., AUA, Atlanta, GA, 5/22/2012
• Cancer Incidence and Mortality among Workers Exposed to 3, 3- Dichlorobenzidine.
  Schoenberg MP, AUA, San Francisco, CA, 5/20/2010
• Pathologic upstaging at the time of radical cystectomy is associated with worse recurrence free survival in patients with BCG-refractory bladder cancer.
  Guzzo TJ, Magheli A, Bivalacqua TJ, Nielsen ME, Attenello F, Ball MW, Schoenberg MP, Gonzalgo ML, Annual American Urology Association Meeting, Chicago, IL, 4/1/2009
• Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of over 4800 patients.
  Novara G, Svatek RS, Karakiewicz, PI, Skinner E, Fradet Y, Lotan Y, Capitanio U, Bastian PJ, Montorsi F, Kassouf W, Fritsche H-M, Muller SC, Izawa JI, Isbarn H, Stief ..., Annual American Urology Association Meeting, Chicago, IL, 4/1/2009
• Long-term survival after radical prostatectomy for men with high pathologic gleason sum.
  Pierorazio PM, Guzzo TJ, Han M, Bivalacqua TJ, Epstein JI, Schoenberg MP, Walsh PC, Partin AW, Annual American Urology Association Meeting, Chicago, IL, 4/1/2009
• Lymphovascular invasion is a powerful predictor of clinical outcomes on node-negative radical cystectomy patients: an international external validation study.
  Shariat SF, Svatek RS, Skinner E, Karakiewicz PI, Capitanio U, Bastian PJ, Volkmer BG, Montorski F, Kassouf W, Novara G, Fritsche H-M, Muller SC, Izawa JI, Isbarn H, S..., Annual American Urology Association Meeting, Chicago, IL, 4/1/2009
• Evidence-based gender related outcomes after radical cystectomy: results of a large multicenter study.
  Svatek RS, Shariat SF, Dinney CP, Novara G, Fradet Y, Bastian PJ, Kassouf W, Karakiewicz PI, Fritsche H-M, Muller SC, Izawa JI, Skinner E, Stief CG, Ficarra V, Volkmer..., Annual American Urology Association Meeting, Chicago, IL, 4/1/2009
• Prognostic value of lymph node density in a multicenter international cohort of patients with node positive urothelial carcinoma of the bladder.
  Svatek RS, Shariat SF, Kassouf W, Novara G, Fradet Y, Bastian PJ, Karakiewicz PI, Fritsche H-M, Muller SC, Izawa JI, Dinney CP, Stief CG, Ficarra V, Kamat A, Isbarn H,..., Annual American Urology Association Meeting, Chicago, IL, 4/1/2009
• Outcomes of patients with T1 grade 3 bladder urothelial cell bladder carcinoma treated with radical cystectomy.
  Gupta A, Shariat SF, Nielson M, Bastian PJ, Palapattu GS, Rogers CG, Vazina A, Karakiewicz PI, Schoenberg MP, Lerner SP, Sagalowsky AI, Lotan Y, Annual American Urological Association Meeting, Anaheim, CA, 5/1/2007
• Evidence based gender related outcomes after radical cystectomy.
  Amiel GE, Shariat SF, Shen S, Palapattu GS, Latan Y, Karakiewic PI, Vazina A, Rogers CG, Bastiwn PJ, Nielsen ME, Gupta A, Schoenberg MP, Sagalowsky, AI, Lerbner SP, Annual American Urological Association Meeting, Atlanta, GA, 5/1/2006
• Prognostic significance of deep muscular invasion and intravesical extension in pathological staging of bladder cancer after radical cystectomy.
  Bastian PJ, Shariat SF, Rogers CG, Amiel GE, Karakiewicz PI, Lotan Y, Gupta A, Vazina A, Sagalowsky AI, Lerner SP, Schoenberg MP, Palkapattu GS, Annual American Urological Association Meeting, Atlanta, GA, 5/1/2006
• Internal validation of a competing-risks survival nomogram for patients treated with cystectomy for bladder cancer.
  Briganti A, Chun K-H F, Shariat SF, Lotan Y, Palapattu GS, Rogers CG, Bastian PJ, Gilad A, Gupta A, Vazina A, Sagalowsky AI, Lerner SP, Schoenberg MP, Karakiewicz PI, Annual American Urological Association Meeting, Atlanta, GA, 5/1/2006
• Competing risks nomogram predicting the probability of bladder cancer recurrence after cystectomy can reliably distinguish between those destined to recur and those wh...
  Chun K-H F, Briganti A, Shariat SF, Palapattu GS, Lotan Y, Rogers CG, Bastian PJ, Amiel GE, Gupta A, Vazina A, Nielsen M, Sagalowsky AI, Lerner SP,. Schoenberg MP, Kar..., Annual American Urological Association Meeting, Atlanta, GA, 5/1/2006
• Delay in radical cystectomyover 12 weeks is not associated with adverse outcome: Results from the Bladder Cancer Reserch Consortium.
  Nielsen ME, Shariat SF, Karakiewicz PI, Amiel GE, Rogers CG, Lotan Y, Bastian PJ, Vazina A, Gupta A, Lerner SP, Sagalowsky AI, Schoenberg MP, Palapattu GS, Annual American Urological Association Meeting, Atlanta, GA, 5/1/2006
• Impact of concomitant carcinoma in situ on clinical outcomes after radical cystectomy.
  Shariat SF, Pallapatu GS, Amiel GE, Karakiewicz PI, Rogers CG, Bastian PJ, Vazina A, Gupta A, Schoenberg MP, Lerner SP, Sagalowsky AI, Lotan Y, Annual American Urological Association Meeting, Atlanta, GA, 5/1/2006
• A prognostic tool to identify patients at high risk of relapse at 2, 5 and 8 years after cystectomy for transitional call carcinoma (tcc) of the urinary bladder: nomog...
  Karakiewicz PI, Shariat SF, Perrotte P, Palapattu GS, Rogers CG, Bastian PJ, Lotan Y, Gupta A, Vazina A, Gilad A, Sagalowsky AI, Schoenberg MP and Lerner SP, Annual American Urological Association Meeting, San Antonio, TX, 5/1/2005
• Are patients who are PT0 following radical cystectomy cured of bladder cancer? Results from the Bladder Cancer Research Consortium (BCRC).
  Palapattu GS, Karakiewicz PI, Bastian PJ, Rogers CG, Shariat SF, Lotan Y, Gupta A, Vazina A, Amiel GE, Perrotte P, Sagalowsky AI, Lerner SP and Schoenberg MP, Annual American Urological Association Meeting, San Antonio, TX, 5/1/2005
• Outcomes of patients with aborted cystectomy for intraoperative findings of metastatic disease.
  Rogers CG, Palapattu GS, Bastian PJ, Gonzalgo ML and Schoenberg MP, Annual American Urological Association Meeting, San Antonio, TX, 5/1/2005
• Bladder cancer-specific survival following radical cystectomy for primary non-transitional cell carcinoma (non-tcc) of the bladder: results from the Bladder Cancer Res...
  Rogers CG, Palapattu GS, Karakiewicz PI, Bastian PJ, Shariat SF, Lotan Y, Gupta A, Vazina A, Amiel GE, Perrotte P, Sagalowsky A, Lerner SP and Schoenberg MP, Annual American Urological Association Meeting, San Antonio, TX, 5/1/2005
• The use of Hexvix and Fluorescence Cystoscopy as an Adjunct in the Diagnosis of Stage Ta/T1 urothelial cancer in the urinary bladder.
  Grossman HB, Gomella LG, Fradet Y, Presti JC, Ritenour CWM, Lerner SP, Cookson M, Nseyo UO, Bihrle R, Fuchs GJ, Schoenberg MP and Droller MJ, Annual American Urological Association Meeting, San Francisco, CA, 5/1/2004
• Join now to see all

Lectures

• Update of Nerve Sparing Radical Cystoprostatectomy Outcomes. 
  Bethesda, MD - 12/1/2006
• Bladder cancer. 
  Baltimore, MD - 6/27/2004
• Visiting Professor, Uromythology of Bladder Cancer. 
  NYU Medical Center, New York, NY - 11/4/2003
• Diagnosing Bladder and Prostate Cancer. 
  North Arundel Hospital, Glen Burnie, MD - 9/18/2003
• Uromythology: Bladder Cancer Detection and Treatment. Visiting Professor 
  University of Michigan, Ann Arbor, MI - 11/6/2002
• Evaluation of hematuria. 
  Johns Hopkins Medical Institutions, Baltimore, MD - 5/9/2001
• Cystectomy and the management of muscle invasive bladder cancer. 
  Anaheim, CA - 5/1/2001
• Molecular diagnostics for bladder cancer: Who let the dogs out? 
  Washington, DC - 3/1/2001
• Continent Diversion. 
  10/15/2000
• Clinical significance of premalignant alterations in the genitourinary tract. 
  Stockholm, Sweden - 6/1/2000
• Management of invasive and advanced bladder cancer & alternate methods of urinary diversion. 
  Dallas, TX - 3/7/1998
• Managing invasive and advanced bladder carcinoma. 
  Long Island, NY - 12/10/1997
• International Workshop on Diagnostic and Prognostic Markers in Bladder Cancer 
  Barcelona, Spain - 5/4/1997
• Cystectomy (male and female) in the management of invasive bladder cancer. 
  New Orleans, LA - 4/16/1997
• Molecular diagnosis of bladder cancer and a molecular progression model for bladder carcinoma. 
  Berlin, Germany - 11/29/1996
• The management of invasive and advanced bladder carcinoma. 
  3/29/1996
• Treatment decision-making and outcome of prostate cancer. 
  Chicago, IL - 11/1/1995
• Join now to see all

Other

• Technique of partial nephrectomy. (Videotape, Abstract #V-9) 
  Marshall FF, Brooks JC and Schoenberg MP, J Urol; American Urological Association Meeting, San Francisco, CA
  1/1/1994
• Management of condyloma acuminata. Medical Outlook for Urologists (audiotape) 
  Carpiniello VL and Schoenberg MP
  1/1/1990